跳至主要内容
临床试验/NCT01936935
NCT01936935已完成不适用

A Randomized, Controlled, Crossover Trial to Assess the Effects of Dairy Intake on Insulin Sensitivity and β-Cell Function in Men and Women at Risk for Diabetes Who Are Habitual Consumers of High Sugar Beverages

Provident Clinical Research2 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2012年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
44
试验地点
2
主要终点
Matsuda Insulin Sensitivity Index (MISI)

研究概览

简要总结

The aim of this trial is to evaluate the effects of dairy product consumption on insulin sensitivity and pancreatic β-cell function in men and women at risk for the development of type 2 diabetes mellitus (T2DM) who habitually consume beverages high in sugar (non-diet sodas and fruit juice cocktails).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 74 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • subject is male or female, 18-74 yrs of age, inclusive
  • subject reports habitual consumption of ≥2 servings/d of high-sugar beverages (e.g., non-diet soda, fruit juice cocktails)
  • subject has waist circumference ≥33.0 inches for women and ≥36.0 inches for men
  • subject is at risk for development of type 2 diabetes mellitus (T2DM), based on 1 or more of the following: fasting glucose 100-125 mg/dL; glycosylated hemoglobin 5.7-6.4%, or ≥20% risk of developing diabetes in the next 7.5 yrs based on the San Antonio Heart Study prediction equation
  • subject has a score of 7-10 on the Vein Access Scale at screening
  • subject is normally active and judged to be in good health on the basis of medical history, physical examination and routine lab tests
  • if female, subject is willing to schedule treatment visits during the follicular phase of the menstrual cycle, defined as days 1-14, where day 1 is 1st day of menses
  • subject has a menstrual cycle duration ranging in length form 24-36 d (if premenopausal)
  • subject is willing to maintain a stable body weight and follow his/her habitual diet and exercise pattern, except for inclusion of study product, throughout the trial
  • subject is willing to maintain his or her habitual intake of coffee, tea, and alcoholic beverages throughout the trial
  • subject agrees to limit intake of non-study related dairy products to ≤1 serving per day during each treatment period
  • subject is ambulatory and willing to refrain from vigorous physical activity and consumption of alcoholic beverages 24 h prior to each test day
  • subject has no plans to change smoking habits during the study period
  • subject is willing to abstain from tobacco use 1 h prior to and during visits on LMTT test days
  • subject has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the Investigator on the basis of medical history and routine lab test results

排除标准

  • subject has abnormal lab test results of clinical importance, including, but not limited to, TG ≥400 mg/dL, fasting creatinine ≥1.5 mg/dL, alanine aminotransferase or aspartate aminotransferase ≥1.5 times the upper limit of normal at screening
  • subject has a body mass index ≥45.0 kg/m2
  • subject has fasting blood glucose ≥126 mg/dL at screening or known diabetes mellitus (type 1 or T2DM)
  • subject has a habitual intake of ≥4 servings/d of dairy food and beverages
  • subject has known allergy or sensitivity to study product or any ingredients of study product. Subjects with lactose intolerance will be allowed to use products such as Lactaid dietary supplements
  • subject has a history of coronary heart disease, congestive heart failure, or serious ventricular dysrhythmias (ventricular tachycardia or fibrillation)
  • subject has a change in body weight of >4.5 kg within 4 weeks of screening
  • subject uses medications known to influence carbohydrate metabolism
  • subject has recent use of antibiotics
  • subject has an active infection
  • subject has unstable use of anti-hypertensive medications, thyroid hormone replacement, or lipid-altering drugs within 4 weeks of screening
  • subject has unstable use of lipid-altering foods or dietary supplements within 4 weeks of screening
  • subject uses niacin at doses >200 mg/d within 4 weeks of screening
  • subject has history of extreme dietary habits, e.g., Atkins, high protein
  • subject has a history or presence of clinically important endocrine, cardiac, renal, hepatic, pulmonary, biliary, pancreatic, gastrointestinal, or neurologic disorders that could interfere with interpretation of study results
  • subject has history of dysphagia, swallowing disorders, or intestinal motility disorders
  • subject has history of cancer
  • subject has uncontrolled hypertension at screening (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg)

结局指标

主要结局

Matsuda Insulin Sensitivity Index (MISI)

时间窗: 6 weeks

MISI calculated from glucose and insulin data obtained during a liquid meal tolerance test (LMTT). MISI = 10,000 divided by the square root of the quantity of fasting glucose x fasting insulin x mean post-load glucose from samples collected at 30, 60, 90 and 120 min after the start of the liquid meal x mean post-load insulin from samples collected at 30, 60, 90 and 120 min after the start of the liquid meal

次要结局

  • Blood pressure(6 weeks)
  • Glucose total area under the curve (AUC) from 0-120 min(6 weeks)
  • Insulin total AUC 0-120 min(6 weeks)
  • 30 min Δ insulin/Δ glucose(6 weeks)
  • Plasma high-sensitivity C-reactive protein (hs-CRP)(6 weeks)
  • Fasting and 2-hr LMTT insulin and glucose concentrations(6 weeks)
  • Homeostasis model assessment of insulin resistance (HOMA-IR)(6 weeks)
  • Homeostasis model assessment of beta-cell function (HOMA%B)(6 weeks)
  • Disposition Index(6 weeks)
  • Fasting plasma high-density lipoprotein cholesterol (HDL-C)(6 weeks)
  • Fasting plasma TG(6 weeks)
  • AUC insulin/AUC glucose(6 weeks)
  • Fasting plasma total cholesterol (total-C)(6 weeks)
  • Fasting plasma non-HDL-C(6 weeks)
  • Serum 25-hydroxy vitamin D [25(OH)D](6 weeks)
  • Waist circumference(6 weeks)
  • Fasting plasma low-density lipoprotein cholesterol (LDL-C)(6 weeks)
  • Fasting plasma total-C/HDL-C(6 weeks)

研究者

发起方
Provident Clinical Research
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验